[Skip to Content]
[Skip to Content Landing]
October 1988

Efficacy of Leuprolide Therapy in Children With Central Precocious Puberty

Author Affiliations

From Children's Health Center of St Joseph's Hospital, Phoenix (Dr Kappy and Mr Stuart), and Phoenix Children's Hospital (Dr Perelman).

Am J Dis Child. 1988;142(10):1061-1064. doi:10.1001/archpedi.1988.02150100055025

• Eight girls with central precocious puberty were treated with the long-acting gonadotropin releasing hormone analogue leuprolide acetate (Lupron) for a period of six to 18 months. Suppression of gonadotropin and estradiol secretion and regression of secondary sexual characteristics and menses were observed while patients received a subcutaneous dose of 35 to 40 μg/kg/d. Growth velocity was slowed in all but one patient, and the rate of skeletal maturation was slowed even more, resulting in a stabilization or improvement in predicted adult height. There were no major side effects. Although the long-term effects of leuprolide therapy cannot be determined with this study, it appears to be efficacious in the treatment of central precocious puberty.

(AJDC 1988;142:1061-1064)